Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 619 results
Found 619 results.

2016

De Boni RB, Zheng L, Rosenkranz SL, et al. "Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals." Drug Alcohol Depend. 2016;159:174-80.
McComsey GA, Moser C, Currier J, et al. "Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s." Clin. Infect. Dis.. 2016;62(7):853-62.
Treasure GC, Aga E, Bosch RJ, et al. "Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials." J. Acquir. Immune Defic. Syndr.. 2016;72(3):310-3.
Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Judge CJ, Sandberg JK, Funderburg NT, et al. "CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy." J. Acquir. Immune Defic. Syndr.. 2016.
Dirajlal-Fargo S, Moser C, Brown TT, et al. "Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s." Open Forum Infect Dis. 2016;3(3):ofw174.
Kelesidis T, Moser C, Stein JH, et al. "Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." J. Infect. Dis.. 2016.
Kelesidis T, Tran TTien T, Brown TT, et al. "Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s." Antivir. Ther. (Lond.). 2016.
Robbins GK, Cohn SE, Harrison LJ, et al. "Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251." HIV Clin Trials. 2016;17(4):165-72.
Balagopal A, Gupte N, Shivakoti R, et al. "Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort." Open Forum Infect Dis. 2016;3(3):ofw118.
Riddler SA, Aga E, Bosch RJ, et al. "Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy." J. Infect. Dis.. 2016;213(4):556-60.
Girouard MP, Sax PE, Parker RA, et al. "The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States." Clin. Infect. Dis.. 2016;62(6):784-91.
Chan ES, Landay AL, Brown TT, et al. "Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir." AIDS. 2016;30(13):2091-7.
Bednar MM, Hauser BM, Zhou S, et al. "Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation." J. Infect. Dis.. 2016;214(3):403-7.
Schnitzer ME, Lok JJ, Bosch RJ. "Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring." Biostatistics. 2016;17(1):165-77.
Jacobson JM, Bosinger SE, Kang M, et al. "The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1." AIDS Res. Hum. Retroviruses. 2016;32(7):636-47.
Weinberg A, Park J-G, Bosch R, et al. "Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women." J. Acquir. Immune Defic. Syndr.. 2016;71(2):137-45.
Bedimo R, Kang M, Tebas P, et al. "Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients." AIDS Res. Hum. Retroviruses. 2016;32(4):325-8.
Hosseinipour MC, Bisson GP, Miyahara S, et al. "Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial." Lancet. 2016;387(10024):1198-209.
Luetkemeyer AF, Firnhaber C, Kendall MA, et al. "Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings." Clin. Infect. Dis.. 2016;62(9):1081-8.
Landovitz RJ, Tran TTien T, Cohn SE, et al. "HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States." AIDS Behav. 2016.
Lee SA, Mefford JA, Huang Y, et al. "Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans." AIDS. 2016;30(11):1807-15.
Vardhanabhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis CL. "Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230." Open Forum Infect Dis. 2016;3(3):ofw154.
Shiboski CH, Lee A, Chen H, et al. "Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy." AIDS. 2016;30(10):1573-82.
Matoga MM, Hosseinipour MC, Aga E, et al. "Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings." Antivir. Ther. (Lond.). 2016.
Mave V, Erlandson KM, Gupte N, et al. "Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults." J. Infect. Dis.. 2016;214(1):65-72.
Petersen T, Lee Y-J, Osinusi A, et al. "Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin." AIDS Res. Hum. Retroviruses. 2016;32(7):660-7.
Robertson K, Jiang H, Evans SR, et al. "International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271." J. Neurovirol.. 2016;22(4):472-8.
Grant PM, Kitch D, McComsey GA, et al. "Long-term body composition changes in antiretroviral-treated HIV-infected individuals." AIDS. 2016;30(18):2805-2813.

Pages